Evidence map›Paper›PMID 32959668›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor-Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?

Yulin Wan, Shanshan An, Yanchao Zhou, Jiaming Zhang, Ying Zhang, Tao Gan, Qiuyun Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yulin WanSchool of Life Sciences, 26469Sun Yat-sen University, Guangzhou, China.
Shanshan AnSchool of Life Sciences, 26469Sun Yat-sen University, Guangzhou, China.
Yanchao ZhouSchool of Life Sciences, 26469Sun Yat-sen University, Guangzhou, China.
Jiaming ZhangSchool of Chemistry, 26469Sun Yat-sen University, Guangzhou, China.
Ying Zhang214164Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
Tao GanSchool of Basic Medicine, 74554Gannan Medical University, Ganzhou, Jiangxi, China.
Qiuyun LiuSchool of Life Sciences, 26469Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0001-5533-0128
Sun Yat-sen University · CNGannan Medical University · CNGuangzhou Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous cases of checkpoint inhibitor-triggered cancer hyperprogression have been documented. A previous hypothesis attributes cancer onset to the local buildup of hydrogen chloride, jointly mediated by hydrogen bond donors and acceptors and basic amino acids. The anti-PD1/PD-L1 immunotherapies may have caused a surge of protons or chloride ions for the effective treatment of neoplasm, thus giving rise to the local formation of hydrogen chloride and subsequently cancer hyperprogression in some susceptible individuals. It was postulated that the local strength of acidity is critical for tumor growth and metastasis, as the intake of weak organic acids reduces cancer risks. The anti-PD1/PD-L1 immunotherapies can be integrated with weak organic acids to reduce adverse reactions and generate better anticancer outcomes.

Indexed as

AcidsB7-H1 AntigenDisease ProgressionDrug-Related Side Effects and Adverse ReactionsHumansImmune Checkpoint InhibitorsNeoplasmsPrognosisProgrammed Cell Death 1 ReceptorAcidsB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptoracidityanti-PD1/PD-L1 immunotherapiescancer hyperprogressioncheckpoint inhibitorweak organic acids

Identifiers

PMID32959668
PMCPMC7513399
OpenAlexW3087735955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.